BAYRY Живые сигналы | Максимизируйте прибыль с Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 апр. 2024 @ 19:51):

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments...

Stats
Объем за сегодня	235 998
Средний объем	2.07M
Рыночная капитализация	29.20B
EPS	$0 ( 2024-03-05 )
Дата следующего отчета о доходах	( $0 ) 2024-05-09
Last Dividend	$0.632 ( 2023-05-02 )
Next Dividend	$0 ( N/A )
P/E	-9.29
ATR14	$0.00600 (0.08%)

Объем Корреляция

Длинно: 0.01 (neutral)

Кратко: 0.37 (neutral)

Signal:(44.332) Neutral

Bayer Aktiengesellschaft Корреляция

10 Самые положительные корреляции

10 Самые отрицательные корреляции

Вы знали?

Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).

Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.

Bayer Aktiengesellschaft Корреляция - Валюта/Сырье

0.84
( strong )

0.00
( neutral )

0.85
( strong )

-0.61
( weak negative )

-0.87
( strong negative )

Bayer Aktiengesellschaft Финансовые показатели

Annual	2023
Выручка:	$47.64B
Валовая прибыль:	$27.89B (58.54 %)
EPS:	$-2.99

FY	2023
Выручка:	$47.64B
Валовая прибыль:	$27.89B (58.54 %)
EPS:	$-2.99

FY	2022
Выручка:	$50.74B
Валовая прибыль:	$30.87B (60.84 %)
EPS:	$4.22

Financial Reports:

No articles found.

Bayer Aktiengesellschaft Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0.632 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Bayer Aktiengesellschaft Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 3.23 - low (7.68%) | Divividend Growth Potential Score: 2.39 - Decrease likely (52.29%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.320	2001-04-25
Last Dividend	$0.632	2023-05-02
Next Dividend	$0	N/A
Payout Date	2023-05-15
Next Payout Date	N/A
# dividends	24	--
Total Paid Out	$12.19	--
Avg. Dividend % Per Year	0.00%	--
Score	1.58	--
Div. Sustainability Score	3.23
Div.Growth Potential Score	2.39
Div. Directional Score	2.81	--

Next Divdend (Est)
(2025-03-31)

$0.640 Estimate 3.12 %

Dividend Stability

0.25 Very Poor

Dividend Score

1.58

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for OTC

Symbol	Title	Last dividend	Frequency	Yearly Dividend
SOUHY	Ex Dividend Junior	2023-09-14	Annually	0.00%
HFBA	Ex Dividend Junior	2023-09-14	Semi-Annually	0.00%
ANSLY	Ex Dividend Knight	2023-08-23	Semi-Annually	0.00%
NSARO	Ex Dividend Knight	2023-07-07	Quarterly	0.00%
CYFL	Ex Dividend Knight	2023-09-05	Quarterly	0.00%
THYCF	Ex Dividend Junior	2023-09-28	Annually	0.00%
IGGHY	Ex Dividend Knight	2023-09-21	Semi-Annually	0.00%
BDULF	Ex Dividend Knight	2023-09-12	Annually	0.00%
PPWLM	Ex Dividend Junior	2023-07-19	Quarterly	0.00%
EKTAY	Ex Dividend Knight	2023-08-25	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.0617	1.500	-1.235	-1.852	[0 - 0.5]
returnOnAssetsTTM	-0.0238	1.200	-0.795	-0.954	[0 - 0.3]
returnOnEquityTTM	-0.0816	1.500	-2.02	-3.03	[0.1 - 1]
payoutRatioTTM	-0.809	-1.000	-8.09	8.09	[0 - 1]
currentRatioTTM	1.259	0.800	8.70	6.96	[1 - 3]
quickRatioTTM	0.784	0.800	-0.0946	-0.0757	[0.8 - 2.5]
cashRatioTTM	0.201	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.355	-1.500	4.08	-6.11	[0 - 0.6]
interestCoverageTTM	0.595	1.000	-0.891	-0.891	[3 - 30]
operatingCashFlowPerShareTTM	4.85	2.00	8.38	10.00	[0 - 30]
freeCashFlowPerShareTTM	2.05	2.00	8.97	10.00	[0 - 20]
debtEquityRatioTTM	1.332	-1.500	4.67	-7.01	[0 - 2.5]
grossProfitMarginTTM	0.585	1.000	3.58	3.58	[0.2 - 0.8]
operatingProfitMarginTTM	0.0333	1.000	-1.333	-1.333	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.109	1.000	-0.507	-0.507	[0.2 - 2]
assetTurnoverTTM	0.386	0.800	-0.759	-0.607	[0.5 - 2]
Total Score				3.23

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-2.30	1.000	-0.333	0	[1 - 100]
returnOnEquityTTM	-0.0816	2.50	-1.297	-3.03	[0.1 - 1.5]
freeCashFlowPerShareTTM	2.05	2.00	9.32	10.00	[0 - 30]
dividendYielPercentageTTM	9.49	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	4.85	2.00	8.38	10.00	[0 - 30]
payoutRatioTTM	-0.809	1.500	-8.09	8.09	[0 - 1]
pegRatioTTM	0.243	1.500	-1.711	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.100	1.000	10.00	0	[0.1 - 0.5]
Total Score				2.39

Bayer Aktiengesellschaft

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.